Back to Browse Journals » Biologics: Targets and Therapy » Volume 7

Optimizing therapeutics in the management of patients with multiple sclerosis: a review of drug efficacy, dosing, and mechanisms of action

Authors Damal K, Stoker E, Foley JF

Published Date November 2013 Volume 2013:7 Pages 247—258

DOI http://dx.doi.org/10.2147/BTT.S53007

Received 15 August 2013, Accepted 14 September 2013, Published 27 November 2013

Kavitha Damal, Emily Stoker, John F Foley

Rocky Mountain Multiple Sclerosis Research Group, Salt Lake City, UT, USA


Abstract: Multiple sclerosis (MS) is a debilitating neurological disorder that affects nearly 2 million adults, mostly in their prime of youth. An environmental trigger, such as a viral infection, is hypothesized to initiate the abnormal behavior of host immune cells: to attack and damage the myelin sheath surrounding the neurons of the central nervous system. While several other pathways and disease triggers are still being investigated, it is nonetheless clear that MS is a heterogeneous disease with multifactorial etiologies that works independently or synergistically to initiate the aberrant immune responses to myelin. Although there are still no definitive markers to diagnose the disease or to cure the disease per se, research on management of MS has improved many fold over the past decade. New disease-modifying therapeutics are poised to decrease immune inflammatory responses and consequently decelerate the progression of MS disease activity, reduce the exacerbations of MS symptoms, and stabilize the physical and mental status of individuals. In this review, we describe the mechanism of action, optimal dosing, drug administration, safety, and efficacy of the disease-modifying therapeutics that are currently approved for MS therapy. We also briefly touch upon the new drugs currently under investigation, and discuss the future of MS therapeutics.


Keywords: multiple sclerosis, immunomodulation, interferons, glatiramer acetate, monoclonal antibodies, dimethyl fumarate

Download Article [PDF] View Full Text [HTML] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Readers of this article also read:

Efficacy of intensity-modulated radiotherapy combined with chemotherapy or surgery in locally advanced squamous cell carcinoma of the head-and-neck

Yang H, Diao LQ, Shi M, Ma R, Wang JH, Li JP, Xiao F, Xue Y, Xu M, Zhou B

Biologics: Targets and Therapy 2013, 7:223-229

Published Date: 18 October 2013

Cross-reactivity of human monoclonal antibodies generated with peripheral blood lymphocytes from dengue patients with Japanese encephalitis virus

Pipattanaboon C, Sasaki T, Nishimura M, Setthapramote C, Pitaksajjakul P, Leaungwutiwong P, Limkittikul K, Puiprom O, Sasayama M, Chaichana P, Okabayashi T, Kurosu T, Ono K, Ramasoota P, Ikuta K

Biologics: Targets and Therapy 2013, 7:175-187

Published Date: 15 August 2013

Bosutinib in the management of chronic myelogenous leukemia

Keller-von Amsberg G, Schafhausen P

Biologics: Targets and Therapy 2013, 7:115-122

Published Date: 6 May 2013

Clofilium inhibits Slick and Slack potassium channels

Tejada MA, Stolpe K, Meinild AK, Klaerke DA

Biologics: Targets and Therapy 2012, 6:465-470

Published Date: 13 December 2012

OnabotulinumtoxinA in the treatment of neurogenic bladder

Gulamhusein A, Mangera A

Biologics: Targets and Therapy 2012, 6:299-306

Published Date: 28 August 2012

Natural killer cells: role in local tumor growth and metastasis

Langers I, Renoux VM, Thiry M, Delvenne P, Jacobs N

Biologics: Targets and Therapy 2012, 6:73-82

Published Date: 5 April 2012